The RNA-binding protein HuR in human cancer: A friend or foe?

[Display omitted] The RNA-binding proteins (RBPs) are critical trans factors that associate with specific cis elements present in mRNAs whose stability and translation are subject to regulation. The RBP Hu antigen R (HuR) is overexpressed in a wide variety of human cancers and serves as a prognostic...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2022-05, Vol.184, p.114179-114179, Article 114179
Main Authors: Wu, Xiaoqing, Xu, Liang
Format: Article
Language:English
Subjects:
Animals
Cancer
Carcinogenesis
Cell Survival
Companion assay
Drug development
Drug discovery
Drug resistance
ELAV-Like Protein 1 - genetics
ELAV-Like Protein 1 - metabolism
Humans
HuR
Mice
Molecular therapy
Neoplasms - drug therapy
RNA, Messenger - metabolism
RNA-binding protein
RNA-Binding Proteins - genetics
RNA-Binding Proteins - metabolism
Small molecules
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] The RNA-binding proteins (RBPs) are critical trans factors that associate with specific cis elements present in mRNAs whose stability and translation are subject to regulation. The RBP Hu antigen R (HuR) is overexpressed in a wide variety of human cancers and serves as a prognostic factor of poor clinical outcome. HuR promotes tumorigenesis by interacting with a subset of oncogenic mRNAs implicated in different cancer hallmarks, and resistance to therapy. Reduction of HuR levels in cancer cells leads to tumor regression in mouse xenograft models. These findings prompt a working model whereby cancer cells use HuR, a master switch of multiple oncogenic mRNAs, to drive drug resistance and promote cell survival and metastasis, thus rendering the tumor cells with high cytoplasmic HuR more progressive and resistant to therapy. This review summarizes the roles of HuR in cancer and other diseases, therapeutic potential of HuR inhibition, and the current status of drug discovery on HuR.
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2022.114179